These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 10333246)
1. Tumor suppressor genes and breast cancer. Buchholz TA; Weil MM; Story MD; Strom EA; Brock WA; McNeese MD Radiat Oncol Investig; 1999; 7(2):55-65. PubMed ID: 10333246 [TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831 [TBL] [Abstract][Full Text] [Related]
3. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424 [TBL] [Abstract][Full Text] [Related]
4. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490 [TBL] [Abstract][Full Text] [Related]
5. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related]
6. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Kontorovich T; Cohen Y; Nir U; Friedman E Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075 [TBL] [Abstract][Full Text] [Related]
7. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836 [TBL] [Abstract][Full Text] [Related]
8. [What do we know about ATM protein expression in breast tissue?]. Angèle S; Tanière P; Hall J Bull Cancer; 2001 Jul; 88(7):671-5. PubMed ID: 11495820 [TBL] [Abstract][Full Text] [Related]
9. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392 [TBL] [Abstract][Full Text] [Related]
10. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families. Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508 [TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC). Shen D; Vadgama JV Oncol Res; 1999; 11(2):63-9. PubMed ID: 10489161 [TBL] [Abstract][Full Text] [Related]
12. The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer. Kreiss Y; Barak F; Baruch RG; Levy-Lahad E; Pras E; Friedman E Genet Test; 2000; 4(4):403-7. PubMed ID: 11216667 [TBL] [Abstract][Full Text] [Related]
13. High incidence of cancer in a family segregating a mutation of the ATM gene: possible role of ATM heterozygosity in cancer. Bay JO; Uhrhammer N; Pernin D; Presneau N; Tchirkov A; Vuillaume M; Laplace V; Grancho M; Verrelle P; Hall J; Bignon YJ Hum Mutat; 1999; 14(6):485-92. PubMed ID: 10571946 [TBL] [Abstract][Full Text] [Related]
14. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900 [TBL] [Abstract][Full Text] [Related]
16. Contributions of ATM mutations to familial breast and ovarian cancer. Thorstenson YR; Roxas A; Kroiss R; Jenkins MA; Yu KM; Bachrich T; Muhr D; Wayne TL; Chu G; Davis RW; Wagner TM; Oefner PJ Cancer Res; 2003 Jun; 63(12):3325-33. PubMed ID: 12810666 [TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252 [TBL] [Abstract][Full Text] [Related]